145 related articles for article (PubMed ID: 29164927)
1. A Case of a Patient with Residual Symptoms of Schizophrenia who Relapsed Following Treatment with the Topical Corticosteroid, Clobetasol: A Review of its Risk of Systemic Absorption and Possibility of Exacerbating Psychosis.
Spiegel DR; Arsani U; Le S
Clin Schizophr Relat Psychoses; 2017 Nov; ():. PubMed ID: 29164927
[TBL] [Abstract][Full Text] [Related]
2. Interventions for treating oral lichen planus: corticosteroid therapies.
Lodi G; Manfredi M; Mercadante V; Murphy R; Carrozzo M
Cochrane Database Syst Rev; 2020 Feb; 2(2):CD001168. PubMed ID: 32108333
[TBL] [Abstract][Full Text] [Related]
3. Super potent topical corticosteroid use associated with adrenal suppression: clinical considerations.
Gilbertson EO; Spellman MC; Piacquadio DJ; Mulford MI
J Am Acad Dermatol; 1998 Feb; 38(2 Pt 2):318-21. PubMed ID: 9486706
[TBL] [Abstract][Full Text] [Related]
4. Comparison of skin concentrations following topical versus oral corticosteroid treatment: reconsidering the treatment of common inflammatory dermatoses.
McClain RW; Yentzer BA; Feldman SR
J Drugs Dermatol; 2009 Dec; 8(12):1076-9. PubMed ID: 20027934
[TBL] [Abstract][Full Text] [Related]
5. Topical corticosteroids in association with miconazole and chlorhexidine in the long-term management of atrophic-erosive oral lichen planus: a placebo-controlled and comparative study between clobetasol and fluocinonide.
Carbone M; Conrotto D; Carrozzo M; Broccoletti R; Gandolfo S; Scully C
Oral Dis; 1999 Jan; 5(1):44-9. PubMed ID: 10218041
[TBL] [Abstract][Full Text] [Related]
6. Iatrogenic Cushing's syndrome and topical steroid therapy: case series and review of the literature.
Decani S; Federighi V; Baruzzi E; Sardella A; Lodi G
J Dermatolog Treat; 2014 Dec; 25(6):495-500. PubMed ID: 23210698
[TBL] [Abstract][Full Text] [Related]
7. Cushing's syndrome induced by misuse of moderate- to high-potency topical corticosteroids.
Coureau B; Bussières JF; Tremblay S
Ann Pharmacother; 2008 Dec; 42(12):1903-7. PubMed ID: 19017822
[TBL] [Abstract][Full Text] [Related]
8. Adrenal suppression following low-dose topical clobetasol propionate.
Ohman EM; Rogers S; Meenan FO; McKenna TJ
J R Soc Med; 1987 Jul; 80(7):422-4. PubMed ID: 3656312
[TBL] [Abstract][Full Text] [Related]
9. Cushing's syndrome and adrenocortical insufficiency caused by topical steroids: misuse or abuse?
Güven A; Gülümser O; Ozgen T
J Pediatr Endocrinol Metab; 2007 Nov; 20(11):1173-82. PubMed ID: 18183788
[TBL] [Abstract][Full Text] [Related]
10. Exogenous Cushing's syndrome due to topical corticosteroid application: case report and review literature.
Tempark T; Phatarakijnirund V; Chatproedprai S; Watcharasindhu S; Supornsilchai V; Wananukul S
Endocrine; 2010 Dec; 38(3):328-34. PubMed ID: 20972726
[TBL] [Abstract][Full Text] [Related]
11. Relative efficacy and interchangeability ofvarious clobetasol propionate vehicles in the management of steroid-responsive dermatoses.
Feldman SR
Curr Ther Res Clin Exp; 2005 May; 66(3):154-71. PubMed ID: 24672120
[TBL] [Abstract][Full Text] [Related]
12. Clobetasol propionate emollient formulation foam in the treatment of corticosteroid-responsive dermatoses.
Frangos JE; Kimball AB
Expert Opin Pharmacother; 2008 Aug; 9(11):2001-7. PubMed ID: 18627337
[TBL] [Abstract][Full Text] [Related]
13. A case of multiple bone fractures due to the use of topical corticosteroid therapy for psoriasis.
Gönül M; Gönül E
J Dermatolog Treat; 2015 Jun; 26(3):215-6. PubMed ID: 24913132
[TBL] [Abstract][Full Text] [Related]
14. A comparison of oral and topical corticosteroids in patients with bullous pemphigoid.
Joly P; Roujeau JC; Benichou J; Picard C; Dreno B; Delaporte E; Vaillant L; D'Incan M; Plantin P; Bedane C; Young P; Bernard P;
N Engl J Med; 2002 Jan; 346(5):321-7. PubMed ID: 11821508
[TBL] [Abstract][Full Text] [Related]
15. Clobetasol propionate foam, 0.05%.
Melian EB; Spencer CM; Jarvis B
Am J Clin Dermatol; 2001; 2(2):89-92; discussion 93. PubMed ID: 11705308
[TBL] [Abstract][Full Text] [Related]
16. Treatment of bullous pemphigoid with topical clobetasol propionate.
Westerhof W
J Am Acad Dermatol; 1989 Mar; 20(3):458-61. PubMed ID: 2645323
[TBL] [Abstract][Full Text] [Related]
17. Treatment of periocular capillary hemangioma with topical clobetasol propionate.
Cruz OA; Zarnegar SR; Myers SE
Ophthalmology; 1995 Dec; 102(12):2012-5. PubMed ID: 9098309
[TBL] [Abstract][Full Text] [Related]
18. Topical steroid risk analysis: differentiating between physiologic and pathologic adrenal suppression.
Levin E; Gupta R; Butler D; Chiang C; Koo JY
J Dermatolog Treat; 2014 Dec; 25(6):501-6. PubMed ID: 24171390
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics study about topical clobetasol on oral mucosa.
Varoni EM; Molteni A; Sardella A; Carrassi A; Di Candia D; Gigli F; Lodi F; Lodi G
J Oral Pathol Med; 2012 Mar; 41(3):255-60. PubMed ID: 21950548
[TBL] [Abstract][Full Text] [Related]
20. Differences in therapeutic effects of topically applied corticosteroid and tacrolimus on atopic dermatitis-like symptoms in NC/Nga mice.
Noguchi A; Tominaga M; Takahashi N; Matsuda H; Kamata Y; Umehara Y; Ko KC; Suga Y; Ogawa H; Takamori K
J Dermatol Sci; 2017 Apr; 86(1):54-62. PubMed ID: 28069324
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
